Results 251 to 260 of about 343,340 (395)

METTL5 Enables Immune Evasion of Liver Cancer via Chemokine mRNA Translation Regulation

open access: yesAdvanced Science, EarlyView.
METTL5 reshapes the tumor immune microenvironment through ribosome 18S rRNA m6A modification to regulate the translation of chemokine mRNA. Targeting METTL5‐mediated immunosuppression unleashes anti‐tumor immunity and improves the efficacy of anti‐PD‐1 therapy.
Shuang Li   +19 more
wiley   +1 more source

Tumor-infiltrating lymphocytes in cancer immunotherapy: from chemotactic recruitment to translational modeling [PDF]

open access: gold
Fatjona Kraja   +8 more
openalex   +1 more source

Supplementary Data from Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor–Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors

open access: gold, 2023
Sanghyun P. Kim   +37 more
openalex   +1 more source

NAD+‐Dependent Enzyme SIRT3 Limits Intestinal Epithelial Cell Functions Through NAD+ Synthesis Pathway in Colorectal Cancer

open access: yesAdvanced Science, EarlyView.
Microbiota‐derived quinolinic acid is used as an alternative source of replenishing the intracellular NAD+ pool induced by SIRT3 deficiency to regulate intestinal epithelial cell and T cell function, which has implications for targeting intestinal epithelial cells as an approach to the treatment of immune‐associated diseases, including colorectal ...
Ruiying Niu   +12 more
wiley   +1 more source

Supplementary Table S4 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy

open access: gold
Miguel Martín   +22 more
openalex   +1 more source

P12.01 Utilizing radiation to improve adoptive cell therapy with tumor infiltrating lymphocytes [PDF]

open access: hybrid
Nina Obertopp   +6 more
openalex   +1 more source

A Rationally Engineered Spleen‐Tropic One‐Component Lipid‐mRNA Complex (OncoLRC) for Cancer Vaccines

open access: yesAdvanced Science, EarlyView.
OncoLRC, a one‐component lipid‐mRNA complex, enables efficient spleen‐targeted delivery at an exceptionally low lipid‐to‐mRNA mass ratio (1.5:1), robustly activates immune responses, inhibits tumor growth, and synergizes with checkpoint blockade, presenting a next‐generation platform for mRNA vaccines.
Qimeng Yin   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy